ScholarIQanswers from OpenAlex
Chugai Pharmaceutical
FunderResearch funding and supported work
Chugai Pharmaceutical is a funder indexed in ScholarIQ from OpenAlex.
What is known about Chugai Pharmaceutical?
ScholarIQrecord summary
Switzerland company in Japan
How many works does Chugai Pharmaceutical have?
ScholarIQindexed works
Chugai Pharmaceutical has 8,495 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Chugai Pharmaceutical?
ScholarIQopenalex
The OpenAlex for Chugai Pharmaceutical is on the source record.
What is the ROR of Chugai Pharmaceutical?
ScholarIQror
The ROR for Chugai Pharmaceutical is on the source record.
What are the most-cited papers on Chugai Pharmaceutical?
ScholarIQmost cited works
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge, Tak Mao Chan, H. Terence Cook, Fernando C. Fervenza, Keisha L. Gibson, Richard J. Glassock, David Jayne, Vivekanand Jha, Adrian Liew, Zhi-Hong Liu, Juan M. Mejía‐Vilet, Carla Nester, Jai Radhakrishnan, Elizabeth M. Rave, Heather N. Reich, Pierre Ronco, Jan‐Stephan Sanders, Sanjeev Sethi, Yusuke Suzuki, Sydney Tang, Vladimı́r Tesař, Marina Vivarelli, Jack F.M. Wetzels, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Jürgen Floege
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
Felix Carl Saalfeld, Johanna Möller, Petros Christopoulos, Carina Wenzel, Anna Rasokat, Xuefu Wang, Ioannis Vathiotis, David König, Oliver Illini, Christian Grohé, Marcel Wiesweg, Claas Wesseler, Christoph Schubart, Natalie Pelusi, Gernot Rohde, Tobias R. Overbeck, Jutta Kirfel, Jürgen Alt, Diego Kauffmann‐Guerrero, Frank Griesinger, Jonas Kulhavy, Michael Allgäuer, Anna Klimová, Maret Schütz, Daniela E. Aust, Maximilian J. Hochmair, Sacha I. Rothschild, Konstantinos N. Syrigos, Rajwanth Veluswamy, Sebastian Michels, Albrecht Stenzinger, Korinna Jöhrens, Martin Wermke
Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome
Kandai Nozu, Yutaka Takaoka, Hirofumi Kai, Minoru Takasato, Kensuke Yabuuchi, Tomohiko Yamamura, Tomoko Horinouchi, Nana Sakakibara, Takeshi Ninchoji, China Nagano, Kazumoto Iijima
Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria
Yuya Kamura, Tatsuhiro Sakamoto, Yasuhisa Yokoyama, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Naoshi Obara
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
Muthiah Vaduganathan, Jennifer B. Green, Hiddo J.L. Heerspink, Sung Gyun Kim, Johannes F.E. Mann, Janet B. McGill, Amy K. Mottl, Masaomi Nangaku, Julio Rosenstock, Peter Rossing, Li Li, Na Li, Katja Rohwedder, Charlie Scott, Rajiv Agarwal